Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;138(2):351-358.
doi: 10.1007/s11060-018-2803-y. Epub 2018 Feb 19.

Prognostic Role of High Sensitivity C-reactive Protein and interleukin-6 in Glioma and Meningioma Patients

Affiliations

Prognostic Role of High Sensitivity C-reactive Protein and interleukin-6 in Glioma and Meningioma Patients

Adomas Bunevicius et al. J Neurooncol. .

Abstract

High sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) can be important prognostic indicators of brain tumor patients. We investigated the association of circulating IL-6 and hsCRP concentrations with discharge outcomes and survival of glioma and meningioma patients. One-hundred and sixty-three (115 women; median age 57 years) patients admitted for meningioma (n = 94), high-grade glioma (n = 48) and low-grade glioma (n = 21) surgery were enrolled in this prospective cohort study. Serum samples were collected within 24 h of admission. Discharge outcome was evaluated using the Glasgow Outcome Scale (unfavorable outcome = score from 1 to 3). Follow-up continued until November, 2016. Elevated IL-6 (≥ 2 pg/ml) and hsCRP (≥ 1 mg/l) concentrations were present in 25 and 35% of brain tumor patients, respectively. Elevated IL-6 concentrations were associated with unfavorable outcome at hospital discharge, adjusting for brain tumor histological diagnosis, patient age and gender (OR 2.39, 95% CI 0.97-5.91, p = 0.05). Elevated hsCRP concentrations were not associated with discharge outcome (p = 0.13). In multivariate Cox regression analyses adjusted for patient age, gender, extent of tumor resection and adjuvant treatment, elevated IL-6 concentration was associated with greater mortality risk in high-grade glioma patients (OR 2.623; 95% CI 1.129-5.597; p = 0.01), while elevated hsCRP concentration was associated with greater mortality risk in meningioma patients (OR 3.650; 95% CI 1.038-12.831; p = 0.04). Elevated IL-6 concentration is associated with greater unfavorable outcome risk in brain tumor patients and with greater mortality in high-grade glioma patients, while elevated hsCRP concentration is associated with greater mortality in meningioma patients.

Keywords: Brain tumor; Glioma; High sensitivity C-reactive protein; Interleukin-6; Meningioma; Outcome; Survival.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. J Neurosurg. 1994 Sep;81(3):394-401 - PubMed
    1. Br J Cancer. 2007 Feb 12;96(3):474-6 - PubMed
    1. Asian Pac J Cancer Prev. 2013;14(9):5225-30 - PubMed
    1. J Neurosurg. 2009 Jan;110(1):156-62 - PubMed
    1. Clin Neurol Neurosurg. 2016 Jul;146:116-22 - PubMed

MeSH terms

Feedback